Evidence map›Paper›PMID 35048593›Full record

ReviewSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2022

[Research Progress in Immunosuppressive Tumor Microenvironment of Gastrointestinal Cancer].

Yu-Ting Li, Xiang-Yu Tan, Liu-Na Huang, Li-Xiang Ma, Li Fu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Prognostic value and immunological roles of GPX3 in gastric cancer.International journal of medical sciences · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yu-Ting LiGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center of Shenzhen University, and Department of Pharmacology, School of Basic Medical Sciences, Health Science Center, Shenzhen University, Shenzhen 518060, China.
Xiang-Yu TanGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center of Shenzhen University, and Department of Pharmacology, School of Basic Medical Sciences, Health Science Center, Shenzhen University, Shenzhen 518060, China.
Liu-Na HuangGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center of Shenzhen University, and Department of Pharmacology, School of Basic Medical Sciences, Health Science Center, Shenzhen University, Shenzhen 518060, China.
Li-Xiang MaGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center of Shenzhen University, and Department of Pharmacology, School of Basic Medical Sciences, Health Science Center, Shenzhen University, Shenzhen 518060, China.
Li FuGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center of Shenzhen University, and Department of Pharmacology, School of Basic Medical Sciences, Health Science Center, Shenzhen University, Shenzhen 518060, China.
Shenzhen University Health Science Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal (GI) cancer, a common malignant tumor with a high incidence in China, is showing a trend of rising incidence and is afflicting increasingly younger patients. Meanwhile, there have been constant development and innovations in new therapeutic technologies, among which, immunotherapy is now leading in a new era in the treatment of GI cancer. However, the complexity and diversity of immunosuppressive tumor microenvironment (TME) bring many obstacles to the immunotherapy of solid tumors in the GI tract. In this paper, focusing on solid tumors in the GI tract, we reviewed the main factors affecting the formation of immunosuppressive TME, and summarized strategies for targeted immunosuppressive TME-based therapies. Moreover, we analyzed the synergistic mechanism of various combination immunotherapies and reported on the latest progress in and future direction of immunotherapy for GI cancer, intending to provide new perspectives for treating solid tumors in the GI tract with immumotherapy.

Indexed as

Gastrointestinal NeoplasmsNeoplasmsChinaHumansImmunotherapyTumor MicroenvironmentAnti-tumor therapyGastrointestinal cancerImmunosuppressive tumor microenvironmentImmunotherapy

Identifiers

PMID35048593
PMCPMC10408857
OpenAlexW4206610922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.